Disease States

Table of Contents

Breast Cancer

NCT02659514: Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02659514?term=NCT02659514&rank=1

CCI Research Team Contact:

Lesllie Smoot, RN
256-705-4246
leslies@ccihsv.com

Colorectal Cancer

Gastric Cancer

Genitourinary Cancer

NCT0292862 A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02929862?term=LYCERA&rank=3

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT02599324: A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02599324?term=NCT02599324&rank=1

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

Leukemia

NCT02594384: Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimeyslate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02594384?term=LAM&recr=Open&rank=1

Lung Cancer

NCT03382899 A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03382899?term=ARMO&recrs=a&cond=NSCLC&rank=2

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

NCT03382912 A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03382912?term=ARMO&recrs=a&cond=NSCLC&draw=1&rank=1

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

NCT03061812 Study comparing Rovalpituzumab Tesirine versus Topotecan in subjects with Advanced or Metastatic Small Call Lung Cancer with High Levels of Delta-like Protein 3 (DLL3) and who have First Disease Progression during or following Front-line Platinum-based Chemotherapy (TAHOE)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03061812?term=TAHOE&cond=SCLC&rank=1

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

NCT03033511 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03033511?term=Rovalpituzumab&recr=Open&rank=7

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

Lymphoma

NCT03263026: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP versus R-CHOP in Treatment-Naive subjects with high-risk diffuse large B-Cell Lymphoma who posses the Novel Genomic Biomarker DGM1

Trial Information:
https://clinicaltrials.gov/ct2/show/study/NCT03263026?term=DeNovo&recrs=a&cond=DLBCL&rank=5&show_desc=Y&show_locs=Y#desc

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

NCT02793583: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TRG-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02793583?term=Ublituximab&recr=Open&rank=5

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

NCT01994382: A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphoncytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT01994382?term=Portola&recr=Open&rank=1

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

NCT02594384: Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimeyslate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02594384?term=LAM&recr=Open&rank=1

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

Pancreatic Cancer

NCT02993731 A Phase III Study of BBI-608 Plus Nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02993731?term=CanStem111P&rank=1

CCI Research Team Contact:

Lesllie Smoot, RN
256-705-4246
leslies@ccihsv.com

Supportive Care and Disease Registries

NCT02953704 Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy
Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02953704?term=MOST&recrs=a&cond=ET&rank=1

CCI Research Team Contact:

Megan Moseley
256-327-4227
meganh@ccihsv.com

CHS BioBank (ABRT) Trial
Trial Information:
http://www.conversantbio.com/oncology

CCI Research Team Contact:

Megan Moseley
256-327-4227
meganh@ccihsv.com